COMMUNIQUÉS West-GlobeNewswire
-
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026 -
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026 -
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22/07/2026 -
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026 -
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
22/07/2026 -
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026 -
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
22/07/2026 -
Acentra Health Appoints Sreedevi Hegde as Senior Vice President – India Country Head
22/07/2026 -
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
22/07/2026 -
ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
22/07/2026 -
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026 -
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
22/07/2026 -
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07/2026 -
Ipsen finalise l'acquisition de Memo Therapeutics AG, ajoutant un actif premier de sa classe au portefeuille de maladies rares d'Ipsen
22/07/2026 -
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
22/07/2026 -
GlycoReset Supplement Facts Released: Consumer Safety Report Details New Analysis About Glyco Reset Ingredients & Side Effects Risk
22/07/2026 -
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
22/07/2026 -
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
22/07/2026 -
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
22/07/2026
Pages